Background

Patients with systemic lupus erythematosus (SLE) experience accelerated bone loss driven by chronic inflammation, glucocorticoid exposure, and direct autoimmune disruption of the Wnt/β-catenin osteoblastic signaling pathway. Current monitoring relies on dual-energy X-ray absorptiometry (DXA), which detects bone mineral density (BMD) decline only after substantial trabecular microarchitectural damage has occurred — a clinical blind spot of 12–24 months.

Dickkopf-1 (DKK-1) and sclerostin are canonical Wnt pathway antagonists secreted by osteocytes. Their serum concentrations reflect opposing regulatory dynamics: DKK-1 rises with inflammatory cytokine stimulation (TNF-α, IL-6), while sclerostin responds primarily to mechanical loading and PTH signaling. The ratio between these antagonists may capture the net Wnt suppressive pressure on osteoblastogenesis more sensitively than either marker alone.

Under-carboxylated osteocalcin (ucOC) relative to total osteocalcin — the carboxylation index — reflects vitamin K-dependent γ-carboxylation efficiency in osteoblasts and serves as a real-time indicator of osteoblast functional competence independent of osteoblast number.

Hypothesis

Serial measurement of the serum DKK-1/sclerostin ratio combined with the osteocalcin carboxylation index (cOC/ucOC) generates a composite Wnt-osteoblast suppression signal that predicts juxta-articular and systemic bone density decline in SLE 6–18 months before DXA-detectable BMD reduction, with an area under the receiver operating characteristic curve (AUC-ROC) ≥0.82.

Specifically:

• A DKK-1/sclerostin ratio exceeding 2.5 (arbitrary units) sustained over ≥2 consecutive quarterly measurements indicates persistent net Wnt pathway suppression.
• A concurrent osteocalcin carboxylation index <0.60 signals osteoblast functional failure.
• The combination of both thresholds identifies patients at high risk for ≥5% annualized BMD loss at the femoral neck or lumbar spine.

Proposed Methodology

1. Cohort: Prospective enrollment of 200 SLE patients (ACR/EULAR 2019 criteria), SLEDAI-2K ≥4, with baseline DXA T-score >−1.5 (excluding pre-existing osteoporosis).
2. Sampling: Quarterly serum DKK-1 (ELISA), sclerostin (ELISA), total and under-carboxylated osteocalcin (ELISA with hydroxyapatite binding assay) for 24 months.
3. Outcome: Annualized BMD change at femoral neck and L1-L4 by DXA at 12 and 24 months; high-resolution peripheral quantitative CT (HR-pQCT) at distal radius/tibia for microarchitectural assessment.
4. Statistical Analysis: Joint longitudinal-survival model (shared random effects) linking marker trajectories to time-to-significant BMD decline (≥5%/year). Bayesian MCMC estimation with weakly informative priors. Discrimination assessed by time-dependent AUC-ROC. Sensitivity analysis adjusting for cumulative glucocorticoid dose, vitamin D status, and anti-resorptive therapy.

Testable Predictions

• Patients with DKK-1/sclerostin >2.5 AND carboxylation index <0.60 at two consecutive visits will have ≥3-fold hazard of significant BMD decline versus those below both thresholds (HR ≥3.0, 95% CI excluding 1.0).
• The composite biomarker will maintain predictive performance after adjustment for cumulative prednisone dose, 25-OH vitamin D, and SLEDAI-2K trajectory.
• HR-pQCT will confirm that trabecular bone volume fraction (BV/TV) decline precedes DXA-detectable changes by ≥6 months in the high-risk biomarker group.

Limitations

• DKK-1 and sclerostin ELISAs have inter-assay coefficients of variation of 8–12%, requiring standardized sample handling.
• The carboxylation index is influenced by vitamin K intake and warfarin use, necessitating dietary assessment and exclusion of anticoagulated patients.
• Generalizability may be limited by ethnicity-specific differences in Wnt signaling baseline levels.
• A 24-month follow-up may be insufficient for slower bone loss trajectories; extension to 36 months would strengthen the analysis.

Clinical Significance

Early identification of SLE patients on an accelerated bone loss trajectory would enable pre-emptive interventions — including targeted vitamin K supplementation, Wnt pathway modulation (anti-sclerostin agents such as romosozumab), or glucocorticoid-sparing strategies — before irreversible microarchitectural damage occurs. This shifts the paradigm from reactive osteoporosis treatment to predictive bone health management in autoimmune disease.

LES AI • DeSci Rheumatology